Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kijimea
- Development stage
- Unknown
- Lead developer
- SYNformulas
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Kijimea is a branded medical food and probiotic product designed for the dietary management of irritable bowel syndrome (IBS) and its symptoms. Its key active ingredient is the unique bacterial strain Bifidobacterium bifidum MIMBb75 (sometimes also listed as HI-MIMBb75 in heat-inactivated form). This strain has been clinically studied and shown to significantly reduce IBS symptoms such as abdominal pain, bloating, flatulence, constipation, diarrhea, and digestive discomfort while improving quality of life for patients. The mechanism involves restoration and maintenance of gut microbiota balance; the bacteria are believed to exert a "patch effect" on the intestinal wall by settling on areas with micro-lesions or inflammation. Kijimea products are gluten-free and lactose-free. They are manufactured under high-quality standards in Italy and the US based on German research[1][2][3][4][5][6][7].
- Brand names
- KijimeaKijimea IBSKijimea Irritable Bowel SyndromeKijimea Irritable Bowel Pro
Beyond the preview
Go deeper on Kijimea.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kijimea.